Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
16000 participants
INTERVENTIONAL
2022-03-02
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention
NCT01519518
Heparin vs Placebo for Cardiac Catheterization
NCT04374799
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
NCT00790907
In-hospital Clinical Outcome of Deferred Stenting Versus Immediate Stenting in the Management of Acute STEMI Presenting With High Thrombus Burden.
NCT05647018
A Trial of Trans-radial Versus Trans-femoral Percutaneous Coronary Intervention (PCI) Access Site Approach in Patients With Unstable Angina or Myocardial Infarction Managed With an Invasive Strategy
NCT01014273
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Higher Dose Unfractionated Heparin Treatment Period
A centre wide policy of administering 100 U/kg bolus of intravenous unfractionated heparin (UFH) for elective percutaneous coronary intervention (PCI) procedures will be implemented during the Higher Dose UFH treatment period.
Higher Dose UFH
Centre wide policy of administering 100 U/kg bolus of intravenous UFH for elective PCI procedures
Lower Dose Unfractionated Heparin Treatment Period
A centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures will be implemented during the Lower Dose UFH treatment period.
Lower Dose UFH
Centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Higher Dose UFH
Centre wide policy of administering 100 U/kg bolus of intravenous UFH for elective PCI procedures
Lower Dose UFH
Centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Planned chronic total occlusion PCI
* Non-resident precluding follow up through local registries
Hospital (Cluster) Eligibility Criteria
Hospitals will be eligible to participate if they meet the following criteria:
* Submit PCI procedure data to a compatible registry that is able to provide data for the trial
* Site agrees to manage patients as per the higher or lower dose heparin policy in place during the given crossover period
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Population Health Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sanjit Jolly, MD
Role: PRINCIPAL_INVESTIGATOR
Population Health Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hamilton Health Sciences, General Hospital
Hamilton, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HD PCI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.